Genmab's pipeline wins and raised guidance offset a key trial miss
Epcoritamab combo succeeds in DLBCL Genmab's Phase 3 trial of epcoritamab plus lenalidomide met its main goal, cutting the risk of disease progression or death by about 60% in relapsed/refractory DLBCL. This supports a future label expansion and boosts confidence in the drug's commercial potential.
A positive late-stage readout directly raises the odds of future sales growth, a core driver of GMAB's value.
EU approves TEPKINLY for follicular lymphoma European regulators cleared TEPKINLY combined with lenalidomide and rituximab for relapsed/refractory follicular lymphoma, the first bispecific-based regimen approved in Europe for this setting. This opens a new, chemotherapy-free revenue stream for Genmab and AbbVie.
A new regulatory approval expands the addressable market and adds a near-term sales catalyst.
DARZALEX royalties and raised guidance J&J's DARZALEX sales hit $4.2 billion in Q2, lifting Genmab's royalty income. First-half revenue rose 25% to $2.05 billion, prompting management to raise full-year revenue and profit guidance. This steady royalty stream underpins cash flow and reduces reliance on pipeline bets.
Royalty growth and a guidance raise are direct, near-term drivers of earnings and investor confidence.
Epcoritamab monotherapy misses survival endpoint Genmab and AbbVie confirmed that the Phase 3 EPCORE DLBCL-1 trial of epcoritamab alone did not meet its U.S. primary goal of overall survival. The drug keeps its accelerated approval, but the miss clouds the path to full approval in that setting and may delay broader use.
A failed primary endpoint for a key drug is a material setback that can weigh on the stock despite other positive news.